The company announces that Andrew Parker will leave his position as Executive Vice President and Chief Scientific Officer.
Andrew Parker has accepted a top executive leadership position in a non-competing biotechnology company outside Denmark.
“I have thoroughly enjoyed my time at Zealand Pharma, contributing to an exceptional growth story over the last few years and developing a strong pre-clinical pipeline and new external partnerships,” commented Andrew Parker, departing Executive Vice President and Chief Scientific Officer of Zealand Pharma. “The outstanding team and the Zealand peptide platform will continue to deliver new opportunities for long term expansion of the pipeline.”
“Andy has been an exemplary contributor within the corporate management team. Under his leadership, research capabilities expanded with resources successfully focused on specific disease areas. He has helped Zealand to develop strong external partnerships with academia and biotech/pharma. While I deeply regret to lose him, it is always good news to see Zealand people being approached to take on bigger opportunities. I wish him well as he steps into a more demanding, and well deserved new role,” says Emmanuel Dulac, President and Chief Executive Officer at Zealand Pharma.
The process to hire a new Chief Scientific Officer is well underway. Rie Schultz Hansen, Vice President of Research at Zealand Pharma, has been appointed as interim department lead until the new permanent CSO is in place.
Photo of Andrew Parker: Zealand Pharma